8-K: Artivion Reports Strong Fourth Quarter and Full Year 2024 Financial Results, Revenue Up 10%

Artivion announces a 10% increase in full-year revenue and a 32% increase in adjusted EBITDA, driven by growth in key product lines and strategic initiatives.

Summary

• Artivion, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Fourth-quarter revenue reached $97.3 million, a 4% increase on a GAAP basis and 3% on a non-GAAP constant currency basis compared to the fourth quarter of 2023.
• Full-year revenue for 2024 was $388.5 million, a 10% increase on a GAAP basis and 9% on a non-GAAP constant currency basis compared to 2023.
• The company reported a net loss of $(16.5) million, or $(0.39) per fully diluted share, for the fourth quarter of 2024, and a net loss of $(13.4) million, or $(0.32) per fully diluted share, for the full year.
• Adjusted EBITDA increased 15% to $17.6 million in the fourth quarter and 32% to $71.3 million for the full year.
• Artivion generated $22.2 million of operating cash flow and $11.0 million of non-GAAP free cash flow for the full year of 2024.
• The company received Humanitarian Device Exemption (HDE) from the FDA for the AMDS Hybrid Prosthesis and submitted the second module of the pre-market approval application (PMA) to the FDA for AMDS Hybrid Prosthesis.
• Artivion expects revenues for the full year 2025 to be in the range of $420 to $435 million, representing growth of 10% to 14% on a constant currency basis.
• Adjusted EBITDA is expected to grow between 18% and 28% for the full year 2025, resulting in an expected range of $84 to $91 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue and EBITDA growth, regulatory achievements, and a clear strategy for future expansion. While acknowledging the impact of a cybersecurity incident, management expresses confidence in the company's ability to maintain its growth trajectory.

Positives

• Artivion achieved robust revenue and adjusted EBITDA growth in 2024.
• The company delivered positive free cash flow.
• Artivion made significant strides in key clinical and regulatory initiatives, including the FDA's HDE grant for AMDS.
• The company expects sustained double-digit revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth in 2025.
• The company is operating at normal levels across the business after mitigating the late November 2024 cybersecurity incident.

Negatives

• Artivion reported a net loss of $(16.5) million for the fourth quarter of 2024.
• The company experienced a cybersecurity incident in late November 2024 that negatively impacted Q4 revenues.
• Non-GAAP net income for the fourth quarter of 2024 includes pretax losses related to foreign currency revaluation of $5.4 million.

Risks

• The company's financial performance for 2025 and future periods is subject to risks, including the unpredictability of regulatory decisions, risks relating to international operations, and the potential impact of the November 2024 cybersecurity incident.
• The benefits anticipated from clinical trials and regulatory approvals may not be achieved or achieved on anticipated timelines.
• Currency fluctuations are expected to negatively impact year-over-year as reported revenue growth rates by approximately 2% in 2025.

Future Outlook

Artivion anticipates sustained double-digit revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth in 2025, with revenue expected to be between $420 and $435 million and adjusted EBITDA between $84 and $91 million.

Management Comments

• '2024 was an excellent year for Artivion, marked by robust revenue and adjusted EBITDA growth, which enabled us to deliver positive free cash flow while making significant strides in key clinical and regulatory initiatives,' said Pat Mackin, Chairman, President, and Chief Executive Officer.
• Mr. Mackin continued, 'In addition to our commercial results, we were also thrilled to receive a Humanitarian Device Exemption from the FDA for AMDS. This enables us to deliver our groundbreaking, life-saving technology to patients while we continue to work with the FDA toward PMA approval.'
• Mr. Mackin concluded, 'Finally, I'd like to thank our team members for their dedication to mitigating the late November 2024 cybersecurity incident and maintaining our ability to continue serving our customers and their patients.'

Industry Context

Artivion's focus on aortic disease and its portfolio of aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues positions it within the competitive cardiac and vascular surgery market. The company's growth in key product lines and geographic regions reflects its ability to capitalize on market opportunities and address unmet clinical needs.

Comparison to Industry Standards

• Comparing Artivion's 10% revenue growth to companies like Edwards Lifesciences and Medtronic, which also operate in the cardiovascular space, provides context.
• Edwards Lifesciences, a leader in heart valve technologies, has shown similar growth rates in some segments, while Medtronic, with its diversified portfolio, may have different overall growth dynamics.
• Artivion's 32% adjusted EBITDA growth is notable and suggests strong operational efficiency compared to industry peers.
• The company's focus on innovation, as evidenced by the AMDS Hybrid Prosthesis and its regulatory milestones, aligns with the industry's trend toward advanced medical devices.

Stakeholder Impact

• Shareholders can expect continued growth and improved profitability.
• Employees are recognized for their efforts in mitigating the cybersecurity incident.
• Customers and patients will benefit from the company's innovative products and regulatory approvals.
• The company's financial stability and growth prospects may positively impact suppliers and creditors.

Next Steps

• Continue to work with the FDA toward PMA approval for AMDS.
• Execute on the company's best-in-class pipeline.
• Drive sustained double-digit revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth.

Key Dates

Keywords

Artivion, financial results, revenue, EBITDA, AMDS, stent grafts, On-X, BioGlue, FDA, Humanitarian Device Exemption, cybersecurity incident